Physician profile
Benjamin W Powell
NPI 1134668403
$1,029.28
in general payments reported to CMS, 2019-2025
9 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $272 · 2023: $252 · 2024: $305 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $272.93 | 2022-2025 | Vivitrol, Vivitrol, Aristada |
| Otsuka America Pharmaceutical, INC. | $198.43 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $163.14 | 2022-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.69 | 2022-2023 | |
| Indivior INC. | $99.05 | 2023-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $85.25 | 2022-2023 | Ingrezza |
| Abbvie INC. | $63.22 | 2022-2025 | |
| Luye Pharma (USA) LTD. | $23.49 | 2025 | Erzofri Extended-Release |
| Vanda Pharmaceuticals INC. | $20.08 | 2025 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.